Novo Nordisk Shares Plunge on Insulin's FDA Failure

Feb. 11 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk shares have fallen the most in a decade as the company's new insulin drug Tresiba has failed to win FDA approval in the United States. She speaks on Bloomberg Television's "The Pulse."

Full Show: Bloomberg Best (09/30)
25:33 - A review of the week's top business stories from the U.S., Europe and Asia. (Source: Bloomberg)
  • Tackling Age Bias in Silicon Valley
  • Is the Tech IPO Drought Over?
  • What to Expect From Alphabet's Oct. 4 Product Event